The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer

The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer Stratified by Pathologic Risk Factors

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06208436

Enrollment

250

Registered

2024-01-17

Start date

2023-10-07

Completion date

2024-02-28

Last updated

2024-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy, Pancreas Cancer

Brief summary

This study aimed to evaluate the impact of adjuvant chemotherapy on survival in patients with Stage I pancreatic cancer stratified by pathologic risk factors.

Interventions

OTHERAdjuvant chemotherapy

Patients received adjuvant chemotherapy (5-FU-based or gemcitabine-based regimens) or underwent surgery alone

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients who underwent surgical resection and were pathologically diagnosed as PDAC between 2010 and 2021. \-

Exclusion criteria

Patients with pN1-N2, patients with pT3-T4, patients with distant metastasis, patients who received neoadjuvant therapy, patients with R1 resection, and patients who died due to perioperative mortality within 30 days. \-

Design outcomes

Primary

Measure	Time frame	Description
Recurrence-free survival	January 2010 to February 2023	The period between surgical resection to the date of recurrence.

Secondary

Measure	Time frame	Description
Overall survival	January 2010 to February 2023	The period between surgical resection to the date of death.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026